Skip to main content
Erschienen in: Intensive Care Medicine 12/2016

12.09.2016 | What's New in Intensive Care

Why biomarkers failed in sepsis

verfasst von: Jens-Ulrik Jensen, Lila Bouadma

Erschienen in: Intensive Care Medicine | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Excerpt

And yet at the present time the subject is by no means fully elucidated, and it is not even possible to give a general definition of the term septicaemia, which could correctly represent all the different conceptions of its nature current at the present time.
W. W. Van Arsdale (1886) [1].
Literatur
1.
Zurück zum Zitat Van Arsdale WW (1886) I. On the present state of knowledge in bacterial science in its surgical relations (continued): sepsis. Ann Surg 3:321–333CrossRefPubMedPubMedCentral Van Arsdale WW (1886) I. On the present state of knowledge in bacterial science in its surgical relations (continued): sepsis. Ann Surg 3:321–333CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Minor CL, Ringer PH (1909) The prognostic value of the study of the nuclei of the neutrophile leukocytes according to Arneth, in pulmonary tuberculosis. Trans Am Climatol Assoc 25:37–52PubMedPubMedCentral Minor CL, Ringer PH (1909) The prognostic value of the study of the nuclei of the neutrophile leukocytes according to Arneth, in pulmonary tuberculosis. Trans Am Climatol Assoc 25:37–52PubMedPubMedCentral
3.
4.
Zurück zum Zitat Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H, Pawlikowska L, Ware LB, Alkhouli MF, Abbott J, Matthay MA, Network NA (2015) Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med 41:470–478CrossRefPubMedPubMedCentral Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H, Pawlikowska L, Ware LB, Alkhouli MF, Abbott J, Matthay MA, Network NA (2015) Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med 41:470–478CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Forel JM, Guervilly C, Hraiech S, Voillet F, Thomas G, Somma C, Secq V, Farnarier C, Payan MJ, Donati SY, Perrin G, Trousse D, Dizier S, Chiche L, Baumstarck K, Roch A, Papazian L (2015) Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. Intensive Care Med 41:1–11CrossRefPubMed Forel JM, Guervilly C, Hraiech S, Voillet F, Thomas G, Somma C, Secq V, Farnarier C, Payan MJ, Donati SY, Perrin G, Trousse D, Dizier S, Chiche L, Baumstarck K, Roch A, Papazian L (2015) Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. Intensive Care Med 41:1–11CrossRefPubMed
6.
Zurück zum Zitat Nates JL, Cattano D, Chelly JE, Doursout MF (2015) Study of acute hemocoagulation changes in a porcine endotoxemic shock model using thrombelastography. Transl Res 165:549–557CrossRefPubMed Nates JL, Cattano D, Chelly JE, Doursout MF (2015) Study of acute hemocoagulation changes in a porcine endotoxemic shock model using thrombelastography. Transl Res 165:549–557CrossRefPubMed
7.
Zurück zum Zitat Vellinga NA, Boerma EC, Koopmans M, Donati A, Dubin A, Shapiro NI, Pearse RM, Machado FR, Fries M, Akarsu-Ayazoglu T, Pranskunas A, Hollenberg S, Balestra G, van Iterson M, van der Voort PH, Sadaka F, Minto G, Aypar U, Hurtado FJ, Martinelli G, Payen D, van Haren F, Holley A, Pattnaik R, Gomez H, Mehta RL, Rodriguez AH, Ruiz C, Canales HS, Duranteau J, Spronk PE, Jhanji S, Hubble S, Chierego M, Jung C, Martin D, Sorbara C, Tijssen JG, Bakker J, Ince C, Micro SSG (2015) International study on microcirculatory shock occurrence in acutely ill patients. Crit Care Med 43:48–56CrossRefPubMed Vellinga NA, Boerma EC, Koopmans M, Donati A, Dubin A, Shapiro NI, Pearse RM, Machado FR, Fries M, Akarsu-Ayazoglu T, Pranskunas A, Hollenberg S, Balestra G, van Iterson M, van der Voort PH, Sadaka F, Minto G, Aypar U, Hurtado FJ, Martinelli G, Payen D, van Haren F, Holley A, Pattnaik R, Gomez H, Mehta RL, Rodriguez AH, Ruiz C, Canales HS, Duranteau J, Spronk PE, Jhanji S, Hubble S, Chierego M, Jung C, Martin D, Sorbara C, Tijssen JG, Bakker J, Ince C, Micro SSG (2015) International study on microcirculatory shock occurrence in acutely ill patients. Crit Care Med 43:48–56CrossRefPubMed
8.
Zurück zum Zitat Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T, Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V, Sarapuu S, Kobilay M, Ranieri VM, Rello J, Sirgo G, Weiss YG, Russwurm S, Schneider EM, Reinhart K, Holloway PA, Knight JC, Garrard CS, Russell JA, Walley KR, Stuber F, Hill AV, Hinds CJ, Investigators EEG (2015) Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med 3:53–60CrossRefPubMedPubMedCentral Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T, Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V, Sarapuu S, Kobilay M, Ranieri VM, Rello J, Sirgo G, Weiss YG, Russwurm S, Schneider EM, Reinhart K, Holloway PA, Knight JC, Garrard CS, Russell JA, Walley KR, Stuber F, Hill AV, Hinds CJ, Investigators EEG (2015) Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med 3:53–60CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474CrossRefPubMed Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474CrossRefPubMed
10.
Zurück zum Zitat Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD, Procalcitonin And Survival Study (PASS) Group (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–2058CrossRefPubMed Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD, Procalcitonin And Survival Study (PASS) Group (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–2058CrossRefPubMed
11.
Zurück zum Zitat de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827CrossRefPubMed de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827CrossRefPubMed
12.
Zurück zum Zitat Ostrowski SR, Berg RM, Windelov NA, Meyer MA, Plovsing RR, Moller K, Johansson PI (2013) Coagulopathy, catecholamines, and biomarkers of endothelial damage in experimental human endotoxemia and in patients with severe sepsis: a prospective study. J Crit Care 28:586–596CrossRefPubMed Ostrowski SR, Berg RM, Windelov NA, Meyer MA, Plovsing RR, Moller K, Johansson PI (2013) Coagulopathy, catecholamines, and biomarkers of endothelial damage in experimental human endotoxemia and in patients with severe sepsis: a prospective study. J Crit Care 28:586–596CrossRefPubMed
13.
Zurück zum Zitat Ware LB, Koyama T, Zhao Z, Janz DR, Wickersham N, Bernard GR, May AK, Calfee CS, Matthay MA (2013) Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 17:R253CrossRefPubMedPubMedCentral Ware LB, Koyama T, Zhao Z, Janz DR, Wickersham N, Bernard GR, May AK, Calfee CS, Matthay MA (2013) Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 17:R253CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Langley RJ, Tipper JL, Bruse S, Baron RM, Tsalik EL, Huntley J, Rogers AJ, Jaramillo RJ, O’Donnell D, Mega WM, Keaton M, Kensicki E, Gazourian L, Fredenburgh LE, Massaro AF, Otero RM, Fowler VG Jr, Rivers EP, Woods CW, Kingsmore SF, Sopori ML, Perrella MA, Choi AM, Harrod KS (2014) Integrative “omic” analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes. Am J Respir Crit Care Med 190:445–455CrossRefPubMedPubMedCentral Langley RJ, Tipper JL, Bruse S, Baron RM, Tsalik EL, Huntley J, Rogers AJ, Jaramillo RJ, O’Donnell D, Mega WM, Keaton M, Kensicki E, Gazourian L, Fredenburgh LE, Massaro AF, Otero RM, Fowler VG Jr, Rivers EP, Woods CW, Kingsmore SF, Sopori ML, Perrella MA, Choi AM, Harrod KS (2014) Integrative “omic” analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes. Am J Respir Crit Care Med 190:445–455CrossRefPubMedPubMedCentral
Metadaten
Titel
Why biomarkers failed in sepsis
verfasst von
Jens-Ulrik Jensen
Lila Bouadma
Publikationsdatum
12.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 12/2016
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4531-0

Weitere Artikel der Ausgabe 12/2016

Intensive Care Medicine 12/2016 Zur Ausgabe

Correspondence

You neglected a few

Imaging in Intensive Care Medicine

An unusual, iatrogenic cause of massive airleak

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.